Literature DB >> 14622212

Hypocretin-1 causes G protein activation and increases ACh release in rat pons.

René Bernard1, Ralph Lydic, Helen A Baghdoyan.   

Abstract

The effects of the arousal-promoting peptide hypocretin on brain stem G protein activation and ACh release were examined using 16 adult Sprague-Dawley rats. In vitro[35S]GTPgammaS autoradiography was used to test the hypothesis that hypocretin-1-stimulated G protein activation is concentration-dependent and blocked by the hypocretin receptor antagonist SB-334867. Activated G proteins were quantified in dorsal raphe nucleus (DR), locus coeruleus (LC) and pontine reticular nucleus oral part (PnO) and caudal part (PnC). Concentration-response data revealed a significant (P < 0.001) effect of hypocretin-1 (2-2000 nm) in all brain regions examined. Maximal increases over control levels of [35S]GTPgammaS binding were 37% (DR), 58% (LC), 52% (PnO) and 44% (PnC). SB-334867 (2 micro m) significantly (P < 0.002) blocked hypocretin-1 (200 nm)-stimulated [35S]GTPgammaS binding in all four nuclei. This is the first autoradiographic demonstration that hypocretin-1 activates G proteins in arousal-related brain stem nuclei as a result of specific receptor interactions. This finding suggests that some hypocretin receptors in brain stem couple to inhibitory G proteins. In vivo microdialysis was used to test the hypothesis that PnO administration of hypocretin-1 increases ACh release in PnO. Dialysis delivery of hypocretin-1 (100 micro m) significantly (P < 0.002) increased (87%) ACh release. This finding is consistent with the interpretation that one mechanism by which hypocretin promotes arousal is by enhancing cholinergic neurotransmission in the pontine reticular formation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14622212     DOI: 10.1046/j.1460-9568.2003.02905.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  14 in total

1.  Neuropharmacology of Sleep and Wakefulness.

Authors:  Christopher J Watson; Helen A Baghdoyan; Ralph Lydic
Journal:  Sleep Med Clin       Date:  2010-12

Review 2.  Microdialysis as a tool in local pharmacodynamics.

Authors:  Yanjun Li; Joanna Peris; Li Zhong; Hartmut Derendorf
Journal:  AAPS J       Date:  2006-04-07       Impact factor: 4.009

3.  Neuropharmacology of Sleep and Wakefulness: 2012 Update.

Authors:  Christopher J Watson; Helen A Baghdoyan; Ralph Lydic
Journal:  Sleep Med Clin       Date:  2012-09-04

4.  CSF levels of hypocretin-1 (orexin-A) peak during early infancy in humans.

Authors:  Adi Aran; Irina Shors; Ling Lin; Emmanuel Mignot; Michael S Schimmel
Journal:  Sleep       Date:  2012-02-01       Impact factor: 5.849

Review 5.  Orexin/hypocretin receptor signalling cascades.

Authors:  J P Kukkonen; C S Leonard
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

6.  Anxiolytic function of the orexin 2/hypocretin A receptor in the basolateral amygdala.

Authors:  David H Arendt; James Hassell; Hao Li; Justin K Achua; Douglas J Guarnieri; Ralph J Dileone; Patrick J Ronan; Cliff H Summers
Journal:  Psychoneuroendocrinology       Date:  2013-10-30       Impact factor: 4.905

Review 7.  Pontine reticular formation (PnO) administration of hypocretin-1 increases PnO GABA levels and wakefulness.

Authors:  Christopher J Watson; Haideliza Soto-Calderon; Ralph Lydic; Helen A Baghdoyan
Journal:  Sleep       Date:  2008-04       Impact factor: 5.849

8.  Dynamics of neuromodulatory feedback determines frequency modulation in a reduced respiratory network: a computational study.

Authors:  Natalia Toporikova; Robert J Butera
Journal:  Respir Physiol Neurobiol       Date:  2012-11-30       Impact factor: 1.931

9.  Hypocretinergic and non-hypocretinergic projections from the hypothalamus to the REM sleep executive area of the pons.

Authors:  Pablo Torterolo; Sharon Sampogna; Michael H Chase
Journal:  Brain Res       Date:  2012-10-30       Impact factor: 3.252

10.  Hypocretin/Orexin neuropeptides: participation in the control of sleep-wakefulness cycle and energy homeostasis.

Authors:  A Nuñez; M L Rodrigo-Angulo; I De Andrés; M Garzón
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.